Cyclic somatostatin analogues as potent antagonists at μ-, but not δ- and κ-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain
References (21)
- et al.
Selectivity of ligand binding to opioid receptors in brain membranes from rat, monkey and guinea pig
Eur. J. Pharmacol.
(1988) - et al.
Selective effects of [D-Ser2(O-t-butyl),Leu5]enkephalyl-Thr6 and [D-Ser2(O-t-butyl), Leu5jenkephalyl-Thr6(O-t-butyl), two new enkephalin analogues, on neurotransmitter release and adenylate cyclase in rat brain slices
Eur. J. Pharmacol.
(1989) - et al.
A cumulative dose-response technique for the characterization of presynaptic receptors modulating [3H]noradrenaline release from rat brain slices
Eur. J. Pharmacol.
(1982) - et al.
Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward μ-opioid receptors
Life Sci.
(1986) - et al.
Antagonist activity of the cyclic somatostatin analogue CTP at μ-but not δ- and κ-opioid receptors involved in presynaptic inhibition of neurotransmitter reiease
Eur. J. Pharmacol.
(1988) - et al.
Selectivity of various opioid peptides towards δ-,κ- and μ-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain
Neuropeptides
(1989) - et al.
μ-, δ- and κ-opioid receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate
Eur. J. Pharmacol.
(1988) - et al.
Stimulation of D2-dopamine receptors in the rat neostriatum inhibits the release of acetylcholine and dopamine, but does not affect the release of GABA, glutamate or serotonin
Eur. J. Pharmacol.
(1982) Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors
Eur. J. Pharmacol.
(1976)- et al.
Opioid receptor regulation of the release of norepinephrine in brain
Neuropharmacology
(1987)
There are more references available in the full text version of this article.
Cited by (23)
The functional role of ascending nociceptive control in defensive behavior
2012, Brain ResearchCitation Excerpt :The doses were 16 μg NBQX and 680 μg LY376385 (Tambeli et al., 2002). CTOP (Cys2, Tyr3, Orn5, and Pen7 amide) is a μ-opioid receptor antagonist with a selectivity ≈ 4000 × greater than δ-receptors and ≈ 8750 × greater than somatostatin receptors (Gulya et al., 1986; Mulder et al., 1991; Pelton et al., 1986). CTOP was administered into the nucleus accumbens at a dose of 0.5 μg.
μ-, δ-, κ-Opioid receptors and their subtypes. A critical review with emphasis on radioligand binding experiments
1994, Neurochemistry International
Copyright © 1991 Published by Elsevier B.V.